RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Oncopeptides Stock

Oncopeptides Net Income 2025

Oncopeptides Net Income

-79.54 M SEK

Ticker

ONCO.ST

ISIN

SE0009414576

WKN

A2DLU2

In 2025, Oncopeptides's profit amounted to -79.54 M SEK, a -63.87% increase from the -220.13 M SEK profit recorded in the previous year.

The Oncopeptides Net Income history

YEARNET INCOME (undefined SEK)
2027e-
2026e-
2025e-
2024e-
2023-
2022-
2021-
2020-
2019-
2018-
2017-
2016-
2015-
2014-

Oncopeptides Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Oncopeptides, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Oncopeptides from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Oncopeptides’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Oncopeptides. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Oncopeptides’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Oncopeptides’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Oncopeptides’s growth potential.

Oncopeptides Revenue, EBIT and net profit per share

DateOncopeptides RevenueOncopeptides EBITOncopeptides Net Income
2027e514.97 M undefined-9.59 M undefined-10.41 M undefined
2026e234.55 M undefined-102.34 M undefined-24.05 M undefined
2025e111.66 M undefined-206.72 M undefined-79.54 M undefined
2024e35.09 M undefined-268.6 M undefined-220.13 M undefined
202335.22 M undefined-253.45 M undefined-249.11 M undefined
20228.36 M undefined-349.35 M undefined-337.95 M undefined
2021118.3 M undefined-1.42 B undefined-1.43 B undefined
20200 undefined-1.59 B undefined-1.59 B undefined
20190 undefined-739.39 M undefined-740.71 M undefined
20180 undefined-410.96 M undefined-411.11 M undefined
20170 undefined-247.62 M undefined-247.62 M undefined
20160 undefined-114.48 M undefined-114.45 M undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined

Oncopeptides stock margins

The Oncopeptides margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Oncopeptides. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Oncopeptides.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Oncopeptides's sales revenue. A higher gross margin percentage indicates that the Oncopeptides retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Oncopeptides's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Oncopeptides's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Oncopeptides's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Oncopeptides. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Oncopeptides's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Oncopeptides Margin History

Oncopeptides Gross marginOncopeptides Profit marginOncopeptides EBIT marginOncopeptides Profit margin
2027e103.06 %-1.86 %-2.02 %
2026e103.06 %-43.63 %-10.25 %
2025e103.06 %-185.13 %-71.24 %
2024e103.06 %-765.5 %-627.38 %
2023103.06 %-719.61 %-707.3 %
202299.93 %-4,181.33 %-4,044.9 %
202155.09 %-1,201.16 %-1,209.11 %
2020103.06 %0 %0 %
2019103.06 %0 %0 %
2018103.06 %0 %0 %
2017103.06 %0 %0 %
2016103.06 %0 %0 %
2015103.06 %0 %0 %
2014103.06 %0 %0 %

Oncopeptides Aktienanalyse

What does Oncopeptides do?

Oncopeptides AB is a biopharmaceutical company specializing in the research and development of novel therapeutics for the treatment of cancer. The company was founded in 2000 in Uppsala, Sweden. Oncopeptides' research focuses on the discovery of substances that can affect specific cellular processes, inhibiting or even killing the growth of cancer cells. The company places particular emphasis on the development of drugs that can be targeted against specific types of cancer and have minimal side effects. The business model of Oncopeptides is based on licensing developed drugs to other companies or marketing their own products. This allows for faster progress in development and minimizes entrepreneurial risk. The company is divided into three different divisions, focusing on different types of cancer. The first division specializes in the treatment of multiple myeloma, the second in the treatment of solid tumors, and the third in the development of diagnostic tests for early cancer detection. The first product that Oncopeptides has brought to market is the drug Ygalo. It is used to treat patients with advanced multiple myeloma who do not respond to other therapies. Ygalo is a peptide mimetic specifically designed to inhibit the protein MCL-1, which plays a key role in cell proliferation in many types of cancer. In the second division of Oncopeptides, the company focuses on the development of drugs that can be specifically targeted against solid tumors such as lung, breast, or colorectal cancer. The protein BET inhibitor is targeted, which plays an important role in the regulation of gene expression in many types of cancer. The third division of Oncopeptides is engaged in the development of diagnostic tests that enable early detection of cancer. Both blood tests and imaging techniques are used to detect changes in the body that could indicate cancer. The focus is on the development of tests that can detect early signs of cancer, enabling timely diagnosis and treatment. Overall, Oncopeptides is a promising company specializing in the development of innovative therapeutics in cancer treatment. With its focus on specific cellular processes and targeted approaches to fighting different types of cancer, the company is on a promising path to bring more products to market that can improve the lives of many cancer patients. Oncopeptides ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Oncopeptides's Profit Margins

The profit margins of Oncopeptides represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Oncopeptides's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Oncopeptides's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Oncopeptides's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Oncopeptides’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Oncopeptides stock

How much profit has Oncopeptides made this year?

Oncopeptides has made -79.54 M SEK this year.

How has the profit developed compared to last year?

The profit has increased by -63.87% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Oncopeptides publish its earnings?

Oncopeptides publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Oncopeptides?

The profits of Oncopeptides are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Oncopeptides?

You can learn more about the earnings of Oncopeptides by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Oncopeptides pay?

Over the past 12 months, Oncopeptides paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oncopeptides is expected to pay a dividend of 0 SEK.

What is the dividend yield of Oncopeptides?

The current dividend yield of Oncopeptides is .

When does Oncopeptides pay dividends?

Oncopeptides pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oncopeptides?

Oncopeptides paid dividends every year for the past 0 years.

What is the dividend of Oncopeptides?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oncopeptides located?

Oncopeptides is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oncopeptides kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oncopeptides from 1/10/2025 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 1/10/2025.

When did Oncopeptides pay the last dividend?

The last dividend was paid out on 1/10/2025.

What was the dividend of Oncopeptides in the year 2024?

In the year 2024, Oncopeptides distributed 0 SEK as dividends.

In which currency does Oncopeptides pay out the dividend?

The dividends of Oncopeptides are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Oncopeptides

Our stock analysis for Oncopeptides Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oncopeptides Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.